Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management

Future Oncol. 2019 Apr;15(12):1347-1352. doi: 10.2217/fon-2018-0850. Epub 2019 Mar 18.

Abstract

Germ cell tumors represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 and 35. Pure seminoma accounts for around 50% of all testicular germ cell tumors. The prognostic classification of the International Germ Cell Cancer Collaborative Group for good-prognosis seminoma includes both nodal disease and pulmonary visceral metastases. In this article, we analyzed recent data on prognosis and outcome of good-prognosis seminoma to revise the traditional classification of the disease and improve tailored treatment.

Keywords: biomarkers; bleomycin; chemotherapy; germ cell tumors; high-dose; human chorionic gonadotropin; metastases; platinum; prognosis; seminoma; α-fetoprotein.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Disease-Free Survival
  • Humans
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy
  • Male
  • Neoplasm Staging
  • Prognosis
  • Risk Assessment
  • Seminoma / classification*
  • Seminoma / mortality
  • Seminoma / secondary
  • Seminoma / therapy
  • Testicular Neoplasms / classification*
  • Testicular Neoplasms / mortality
  • Testicular Neoplasms / secondary
  • Testicular Neoplasms / therapy
  • Testis / pathology

Substances

  • Biomarkers, Tumor